Key Takeaways Semaglutide produces clinically significant weight loss the STEP 1 trial demonstrated a mean 14.9% body weight reduction at 68 weeks with the 2.4 mg dose The dose escalation schedule is medically necessary, not optional rushing it leads to severe GI side effects that cause most treatment discontinuations Semaglutide is a long-term medication weight returns if treatment is stopped, as shown in the STEP 1 extension trial It carries real contraindications including a family history of medullary thyroid carcinoma, MEN2, pregnancy, and severe GI disease Drug interactions with oral medications are clinically relevant your full medication list must be reviewed by a pharmacist or physician before starting Maximum benefit requires combining semaglutide with a healthy diet and physical activity it reduces appetite, but it does not replace lifestyle modification References Wilding JPH, Batterham RL, Calanna S, et al
a prescription issued and sent to a retail or 503A pharmacy
But this transition to branded weight loss meds drove up costs in Q1
Built by GLP-1 users, for GLP-1 users, and co-created with clinicians, GLPeak blends practical tracking tools with evidence-based guidance so you can navigate your GLP-1 journey with clarity and confidence